Dr Frederik van Delft is an honorary consultant in adolescent oncology & Newcastle University research fellow.
Following his undergraduate studies in Medicine at the Katholieke Universiteit Leuven, Belgium, Dr Van Delft received his postgraduate specialist training in paediatrics/paediatric haematology and oncology at the Vrije Universiteit Brussel, Brussels, Belgium, and Great Ormond Street Hospital in London.
Dr Van Delft read for his PhD in leukaemia molecular genetics at Barts and the London Medical School, Queen Mary University of London. Subsequently he spent one year at the Teenage Cancer Trust Unit at University College London Hospital and six years at the Children’s and Young Person Unit at the Royal Marsden Hospital/Institute of Cancer Research.
Dr Van Delft is a clinician scientist dividing his time between the Great North Children’s Hospital and Newcastle University. His clinical interest concerns the improvement of medical care for teenagers and young adults with leukaemia or lymphoma.
His research programme at the Newcastle University Cancer Centre is aimed at improving our understanding and treatment of leukaemia and lymphoma in children and young adults. Dr Van Delft’s research group has developed the infrastructure to identify drug resistance mechanisms in T-cell malignancies and aims to devise strategies to overcome drug resistance and improve overall outcomes.
He is further interested in understanding the mechanisms underlying venous thromboembolism (VTE) and neurotoxicity with the ultimate aim to prevent or develop efficient management of these important side effects.
Special interests
Teenage and young adult haematological oncology
Further information
Dr Van Delft is a member of the CCLG and NCRI Teenage and Young Adult Clinical Study Group (NCRI TYA CSG) Biological Studies Subgroup.
As a member of the Resistant Disease Committee of the International Berlin-Frankfurt-Munster / SIOPe Childhood Leukaemia Study Group, he works with a group of clinicians and scientists to develop future trials for patients with relapsed T-cell ALL and LBL.
He is local Principal Investigator for the EuroNet Paediatric Hodgkin Lymphoma trials.
Name of secretary
Kelly Brown
